EGRI and FOSB gene expressions in cancer stroma are independent prognostic indicators for epithelial ovarian cancer receiving standard therapy

Stromal components interact with cancer cells to promote growth and metastasis. The purpose of this study was to identify genes expressed in stroma, which could provide prognostic information in epithelial ovarian cancer (EOC). Seventy‐four patients were included. We performed gene expression profiling and confirmed array data using RT‐PCR and immunohistochemistry. By microarray analysis, 52 candidate genes associated with progression free survival (PFS) were identified (P < 0.005). Expression of the early growth response 1 (EGR1) and FBJ murine osteosarcoma viral oncogene homolog B (FOSB) genes was further analyzed. Array data were confirmed by RT‐PCR and multivariate analysis demonstrated that both EGR1 and FOSB expression in cancer stroma, and EGR1 expression in cancer are independent prognostic factors in EOC. Immunohistochemically, EGR1 protein is localized in cancer cells and α‐smooth muscle actin positive stromal fibroblasts. The EGR1 and FOSB expression in stromal cells and EGR1 expression in cancer cells are prognostic indicators in EOC. © 2011 Wiley Periodicals, Inc.

[1]  Mustafa Ozen,et al.  Global Gene Expression Analysis of Reactive Stroma in Prostate Cancer , 2009, Clinical Cancer Research.

[2]  D. Mercola,et al.  Egr1 Signaling in Prostate Cancer , 2003, Cancer biology & therapy.

[3]  M. Stack,et al.  Microenvironmental Regulation of Membrane Type 1 Matrix Metalloproteinase Activity in Ovarian Carcinoma Cells via Collagen-induced EGR1 Expression* , 2007, Journal of Biological Chemistry.

[4]  K. Nishio,et al.  Amplification of GNAS may be an independent, qualitative, and reproducible biomarker to predict progression-free survival in epithelial ovarian cancer. , 2010, Gynecologic oncology.

[5]  H. Moses,et al.  Tumor-stroma interactions. , 2005, Current opinion in genetics & development.

[6]  J. Inazawa,et al.  Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  Kiyoko Kato,et al.  Endometrial cancer side-population cells show prominent migration and have a potential to differentiate into the mesenchymal cell lineage. , 2010, The American journal of pathology.

[8]  J. Corbeil,et al.  The transcription factor Egr1 regulates the HIF‐1α gene during hypoxia , 2009, Molecular carcinogenesis.

[9]  Raghu Kalluri,et al.  Fibroblasts in cancer , 2006, Nature Reviews Cancer.

[10]  H. Nishi,et al.  Early Growth Response-1 gene mediates up-regulation of epidermal growth factor receptor expression during hypoxia. , 2002, Cancer research.

[11]  Kaoru Tanaka,et al.  EGFR mutation up-regulates EGR1 expression through the ERK pathway. , 2009, Anticancer research.

[12]  D. Mercola,et al.  Egr 1 promotes growth and survival of prostate cancer cells : identification of novel Egr 1 target genes , 2003 .

[13]  W. Wong,et al.  Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform. , 2004, Cancer genetics and cytogenetics.

[14]  R. Berkowitz,et al.  Identification of Overexpression and Amplification of ABCF2 in Clear Cell Ovarian Adenocarcinomas by cDNA Microarray Analyses , 2005, Clinical Cancer Research.

[15]  A. Sood,et al.  Stress Effects on FosB- and Interleukin-8 (IL8)-driven Ovarian Cancer Growth and Metastasis* , 2010, The Journal of Biological Chemistry.

[16]  D. Montell,et al.  Ovarian Cancer Metastasis: Integrating insights from disparate model organisms , 2005, Nature Reviews Cancer.

[17]  N. Tsuji,et al.  Overexpression of early growth response-1 as a metastasis-regulatory factor in gastric cancer. , 2002, Anticancer research.

[18]  F. Pépin,et al.  Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.

[19]  M. Saegusa,et al.  Transcription factor Egr1 acts as an upstream regulator of β‐catenin signalling through up‐regulation of TCF4 and p300 expression during trans‐differentiation of endometrial carcinoma cells , 2008, The Journal of pathology.

[20]  Helen Piontkivska,et al.  Analysis of gene expression in prostate cancer epithelial and interstitial stromal cells using laser capture microdissection , 2010, BMC Cancer.

[21]  D. Mercola,et al.  Egr1 Promotes Growth and Survival of Prostate Cancer Cells , 2003, The Journal of Biological Chemistry.

[22]  Levon M Khachigian,et al.  Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth , 2003, Nature Medicine.

[23]  G. Bepler,et al.  EGR1 predicts PTEN and survival in patients with non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Amyj . Williams,et al.  Egr-1-Induced Endothelial Gene Expression: A Common Theme in Vascular Injury , 1996, Science.

[25]  L. Coussens,et al.  Tumor stroma and regulation of cancer development. , 2006, Annual review of pathology.

[26]  M. O'hare,et al.  Tumour-Stromal Interactions in Breast Cancer: The Role of Stroma in Tumourigenesis , 2005, Tumor Biology.

[27]  T. Löning,et al.  The Role of the AP-1 Transcription Factors c-Fos, FosB, Fra-1 and Fra-2 in the Invasion Process of Mammary Carcinomas , 2004, Breast Cancer Research and Treatment.

[28]  Huan-Xing Yang,et al.  Expression of Egr-1, c-fos and cyclin D1 in esophageal cancer and its precursors: An immunohistochemical and in situ hybridization study. , 2004, World journal of gastroenterology.